{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:38:29Z","timestamp":1776371909725,"version":"3.51.2"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.wneu.2024.06.050","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:27:52Z","timestamp":1718731672000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-8037","authenticated-orcid":false,"given":"Joel","family":"Kaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4692-7792","authenticated-orcid":false,"given":"John","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravan","family":"Atluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Ivey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8768-5905","authenticated-orcid":false,"given":"Abby","family":"Zack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rekha","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-5502","authenticated-orcid":false,"given":"Lalanthica","family":"Yogendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha","family":"Wise-Draper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0994-6949","authenticated-orcid":false,"given":"Jonathan A.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supplement_5","key":"10.1016\/j.wneu.2024.06.050_bib1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.wneu.2024.06.050_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/biomedicines9030319","article-title":"Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions","volume":"9","author":"Ogasawara","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.wneu.2024.06.050_bib4","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11060-016-2256-0","article-title":"Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma","volume":"130","author":"Han","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5414\/NP301156","article-title":"Analysis of the inflammatory tumor microenvironment in meningeal neoplasms","volume":"39","author":"Berghoff","year":"2020","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.wneu.2024.06.050_bib7","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512943","article-title":"Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma","volume":"8","author":"Proctor","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.wneu.2024.06.050_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-031-29750-2_17","article-title":"Immunotherapy for meningiomas","volume":"1416","author":"Wirsching","year":"2023","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.wneu.2024.06.050_bib9","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.wneu.2024.06.050_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41467-022-29052-7","article-title":"Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas","volume":"13","author":"Brastianos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.wneu.2024.06.050_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-022-03979-9","article-title":"Immune checkpoint inhibitor therapy for recurrent meningiomas: a retrospective chart review","volume":"157","author":"Nidamanuri","year":"2022","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib13","article-title":"Case Report: recurrent meningioma with multiple metastases","volume":"13","author":"Zhou","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jocn.2016.11.011","article-title":"Regression of intracranial meningioma following treatment with nivolumab: case report and review of the literature","volume":"37","author":"Gelerstein","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2024.06.050_bib15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11060-023-04558-2","article-title":"Volumetric growth rate of incidentally found meningiomas on immunotherapy","volume":"166","author":"Berger","year":"2024","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105938","article-title":"Rapid development of an atypical meningioma during Nivolumab therapy for metastatic renal cell carcinoma","volume":"195","author":"Abele","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2024.06.050_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12883-022-02919-4","article-title":"A\u00a0rare case report of recurrent atypical meningioma with multiple metastases treated with anti-PD-1 and anti-VEGF therapy","volume":"22","author":"Zhao","year":"2022","journal-title":"BMC Neurol"},{"key":"10.1016\/j.wneu.2024.06.050_bib18","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib19","first-page":"4","article-title":"Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review","volume":"122","author":"Rogers","year":"2015","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2024.06.050_bib20","article-title":"The current landscape of immune checkpoint inhibitor immunotherapy for primary and metastatic brain tumors","volume":"12","author":"Alimonti","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.wneu.2024.06.050_bib21","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.wneu.2024.06.050_bib23","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.18632\/oncotarget.27994","article-title":"Future directions for immunotherapy in meningioma treatment","volume":"22","author":"Rutland","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2024.06.050_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2024.06.050_bib25","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2024.06.050_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.wneu.2024.06.050_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024010088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875024010088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T03:10:28Z","timestamp":1729739428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875024010088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":27,"alternative-id":["S1878875024010088"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2024.06.050","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibition for High Grade Meningiomas: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2024.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}